Results 141 to 150 of about 40,773 (330)

Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes

Cardiovascular Diabetology, 2022
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular outcomes in stable coronary artery disease with diabetes.
Li Song, Xiaoxiao Zhao, Runzhen Chen, Jiannan Li, Jinying Zhou, Chen Liu, P. Zhou, Ying Wang, Yi Chen, Hanjun Zhao, Hongbing Yan   +10 more
semanticscholar   +1 more source

Target‐Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A population pharmacokinetic (PK) covariate analysis was conducted utilizing data from adolescents and children ≥8 to <12 years of age with heterozygous familial hypercholesterolemia. One phase II and 1 phase III study were analyzed (121 patients on active treatment).
Pavel Kovalenko, Lutz Harnisch, Jeanne Mendell, Yuhuan Wang, John D. Davis, Albert Thomas DiCioccio   +5 more
wiley   +1 more source

Therapeutic Gene Editing in Dyslipidemias

Reviews in Cardiovascular Medicine
Dyslipidemia, characterized by abnormal lipid levels in the blood, significantly escalates the risk of atherosclerotic cardiovascular disease and requires effective treatment strategies.
Seyed Saeed Tamehri Zadeh, Michael D. Shapiro   +1 more
doaj   +1 more source

PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study [PDF]

, 2020
Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low density lipoprotein receptor (LDLR) through the LDLR epidermal growth factor-like repeat A (EGF-A) domain and induces receptor internalization and degradation.
Altieri GI, Averna M., Barbagallo CM, Brucato F, Cefalu AB, Fayer F, Giammanco A, Ingrassia V, Misiano G, Noto D, Scrimali C, Spina R, Valenti V   +12 more
core   +1 more source

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction

Life, 2022
Cardiovascular diseases are the leading cause of death worldwide, with the majority of the cases being heart failure due to myocardial infarction. Research on cardiovascular diseases is currently underway, particularly on atherosclerosis prevention, to ...
M. U. Puteri, N. Azmi, Mitsuyasu Kato, F. Saputri   +3 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source

Synthetic Biology‐Based Engineering Cells for Drug Delivery

Exploration, EarlyView.
Synthetic biology‐based therapeutic cells for drug delivery: Engineered cells effectively transport and release drugs through their intelligence and controllability, such as feedback pathways and external stimuli (e.g., light and ultrasound). The integration of nanotechnology, including nanoparticles, biofilms, and artificial cells, enhances ...
Wenzhe Yi, Shuangshuang Hu, Xindi Qian, Wenlu Yan, Yaping Li   +4 more
wiley   +1 more source

Proteome‐Wide Mendelian Randomization Identifies Candidate Causal Proteins for Cardiovascular Diseases

Advanced Genetics, EarlyView.
Here, causal relations are examined between 2940 plasma proteins and 19 cardiovascular diseases (CVD) using a human genetics‐based method. 218 proteins are found whose blood levels influence CVD risks, with about half being new discoveries and largely confirmed in an independent cohort.
Chen Li, Nicolas De Jay, Shan‐Shan Zhang, Xin Fang, Supriya Sharma, Katrina A. Catalano, Venkatesh Sridharan, Zhaoqing Wang, Lei Zhao, Joseph D. Szustakowski, Ching‐Pin Chang, Joseph C. Maranville, Emily R. Holzinger, Erika M. Kvikstad   +13 more
wiley   +1 more source

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents [PDF]

, 2011
Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Cao, Guoqing, Konrad, Robert J, Troutt, Jason S   +2 more
core   +3 more sources

Sex-specific predictors of PCSK9 levels in a European population:The IMPROVE study [PDF]

, 2020
Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key regulators of low density lipoprotein cholesterol plasma levels.
, Amato, Mauro, Baldassarre, Damiano, Bonomi, Alice, Capra, Nicolo, Castelnuovo, Samuela, Coggi, Daniela, Colombo, Gualtiero, Ferri, Nicola, Frigerio, Beatrice, Gigante, Bruna, Giral, Philippe, Kurl, Sudhir, Lupo, Maria G., Macchi, Chiara, Pirro, Matteo, Ravani, Alessio, Ruscica, Massimiliano, Sansaro, Daniela, Savonen, Kai, Silveira, Angela, Smit, Andries J., Strawbridge, Rona J., Tremoli, Elena, Veglia, Fabrizio   +24 more
core   +4 more sources